Topical Tacrolimus in Thygeson Superficial Punctate Keratiti
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Thygeson superficial punctate keratitis is chronic, transient, bilateral punctate epithelial keratitis. The lesions are multiple and discrete and made up of intraepithelial opacities, with little or no subepithelial edema and no subepithelial infiltration. Typical symptoms of Thygeson SPK include photophobia, foreign body sensation, burning, tearing, and blurring of vision,

Topical steroids are the mainstay of treatment. However, the prolonged use of topical
There were 3 male and 7 female patients with an age range of 3 to 51 years (mean 17 years). All patients had bilateral ocular involvement. The duration of treatment ranged from 1 to 42 weeks. All patients had subjective improvement in symptoms of tearing and photophobia and resolution of the superficial punctate keratitis. The response to treatment was noted 72 hours after initiation of therapy in all patients. Topical tacrolimus was well tolerated in all patients.

Conclusively, Topical tacrolimus 0.02% is safe and effective in reducing ocular surface inflammation in patients with Thygeson superficial punctate keratitis who are not responsive to conventional therapy. topical tacrolimus is effective in reducing ocular surface inflammation in patients with Thygeson superficial punctate keratitis who are nonresponsive to conventional topical steroid therapy. Tacrolimus is helpful as a steroid-sparing agent to avoid vision-threatening complications.

Source:https://journals.lww.com/corneajrnl/Abstract/2020/06000/Topical_Tacrolimus_in_Thygeson_Superficial.14.aspx
pic credit: webmd.com

Like
Comment
Share